The Billion-Dollar Reason Ozempic and Zepbound Stay Out of Reach

Why are the most effective weight-loss drugs in a generation still so hard to get covered? A new analysis pinpoints the paradox: the drugs are genuinely cost-effective for an individual patient, but the number of people who qualify makes paying for all of them almost impossible.

The distinction that explains everything

Cost-effectiveness and budget impact are different questions, and conflating them is why the debate is so often confused.

Cost-effectiveness asks whether a treatment delivers enough health benefit to justify its price — typically expressed as cost per quality-adjusted life year, compared against a threshold representing what a system is willing to pay for a year of good health.

Budget impact asks a different question: what does covering this cost in total. A drug can pass the first test comfortably and fail the second, if the eligible population is large enough.

Most drugs never raise the issue, because they treat conditions affecting relatively few people. A cost-effective treatment for a rare disease costs the system little in aggregate however expensive per patient.

The maths behind the problem

Roughly 40% of American adults have obesity. That eligible population is exactly what makes broad coverage daunting.

Researchers at the University of Mississippi, writing in the Journal of Managed Care and Specialty Pharmacy, measured GLP-1 spending against the Institute for Clinical and Economic Review budget-impact threshold of about $821 million a year. GLP-1 costs, they found, “blow way past that threshold.”

“GLP-1s provide tremendous value to society, but the budget impact is still massive” because so many people are eligible, said researcher Sujith Ramachandran.

The threshold represents roughly what can be absorbed for one new treatment without displacing spending elsewhere — and displacement is the real consequence, since a health system covering something must reduce something else.

Two extra complications

Many patients stop taking the drugs within the first year, which undercuts the long-term benefit.

That is economically worse than it appears. The cost is incurred during treatment, while benefits accrue over decades of avoided disease — and weight regain after stopping is near-universal, so a year of treatment followed by discontinuation may deliver a fraction of the modelled benefit at full cost.

Second, the promised long-term savings from treating obesity have not yet been proven in available data.

The argument that treatment pays for itself through avoided diabetes, cardiovascular events and joint replacement is plausible and rests on modelling rather than observation. Those savings, if they materialise, arrive many years later — and in a system where people change insurers, the payer bearing the cost is frequently not the one collecting the benefit.

The lifestyle-support finding

Trials pairing the medication with lifestyle support — dietitian access, gym membership — show the best results, but that adds cost too.

It also complicates interpretation of trial results generally, since participants received support that real-world patients typically do not — which is one reason outcomes outside trials tend to be worse.

Why it matters

This is the invisible force behind coverage fights, prior-authorization hurdles and out-of-pocket costs patients keep encountering.

It is not that the drugs do not work — it is that a treatment eligible to tens of millions strains any budget.

What happens when the patents expire

The affordability arithmetic changes substantially over the coming years, and the timeline is worth stating alongside the current problem.

Semaglutide’s core patents begin expiring in major markets during this decade, at different times in different jurisdictions. Generic versions of a peptide are more complex to produce than generics of a small molecule, and competition has still reduced prices dramatically in every drug class where it has arrived.

Some markets will see it sooner. Patent protection varies by country, and manufacturers in jurisdictions where semaglutide is not protected have already begun producing it.

The oral small-molecule agents change the picture differently. Manufactured by conventional chemical synthesis rather than peptide production, their eventual generic versions would be cheap in the way ordinary tablets are cheap — a lower floor than peptide generics can reach.

What that means for the budget problem is that it may be temporary rather than structural. A treatment eligible to tens of millions is unaffordable at current prices; at a tenth of them, the calculation is entirely different — which is an argument for viewing present coverage restrictions as a phase rather than a settled position.

Solving access will likely require lower prices, smarter targeting of who benefits most, or new payment models, not just more demand. Targeting is the most immediately available: eligibility defined by obesity alone is far broader than eligibility defined by obesity plus established cardiovascular disease, and the benefit is not uniform across that range. General information, not medical or financial advice.